Guidelines for ketamine use in clinical psychiatry practice.
Luke A Jelen, Rupert McShane, Allan H Young
BJPsych open May 10, 2024 DOI: 10.1192/bjo.2024.62 via PubMed
Summary
AI-generated from the abstractKetamine shows promise for treatment-resistant depression, but its use requires careful management through evidence-based guidelines. The editorial emphasizes the need for comprehensive protocols to oversee both licensed and off-licence ketamine formulations, referencing recent efforts to develop such guidelines in New Zealand. It advocates for national registries to monitor ketamine therapy, ensuring responsible and effective treatment for depression.
Study at a glance
| Characteristics | Editorial Peer reviewed |
|---|---|
| Intervention | Ketamine |
| Topics | Depression Esketamine Ketamine |
| Keywords | Depressive disorders Antidepressants Guidelines Ketamine therapy |
| Citations | 7 |
| Key finding | Ketamine is effective for treatment-resistant depression, but comprehensive evidence-based guidelines and national registries are needed to manage its use responsibly. |
Abstract
In this editorial, we emphasise the efficacy and challenges of using ketamine in treatment-resistant depression. We highlight the need for comprehensive evidence-based guidelines to manage the use of both licensed and off-licence ketamine formulations and discuss recent efforts by Beaglehole et al to develop ketamine guidelines in New Zealand. We finally advocate for national registries to monitor ketamine therapy, ensuring its responsible and effective use in the management of depression.